Pfizer decides against split-up; more deals seen likely
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/5/2026
- Dow, S&P 500 close at record on AI-linked earnings, Mideast deal hopes
- Caterpillar stock jumps on strong earnings and revenue beat
- Optical component stocks rally on proposed U.S. ban on Chinese tech
- BofA says this memory stock could double. Here are 5 reasons why
- Merck shares rise on big Q2 earnings beat, adjusted FY outlook
- Nutanix to cut 5% of workforce, expects up to $43M in charges
- Opendoor posts Q2 revenue rise as net loss widens year over year
- Walmart dips after Oppenheimer downgrades shares on difficult short-term setup
- Dave & Buster's names CFO Darin Harper as new CEO
- Dow, S&P 500 close at record on AI-linked earnings, Mideast deal hopes
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
Fitch Affirms Ratings on Pfizer (PFE) Amid Decision to Remain Whole
September 27, 2016 11:51 AM EDTThe added diversification that Pfizer Inc.'s (NYSE: PFE) established pharmaceuticals business provides is a relatively less important driver of its credit profile than the company's business development and capital structure, according to Fitch Ratings.
On Monday, Pfizer said it would not be splitting into two companies, delivering its decision to investors as promised prior to the end of the year. However, relative operating prospects and valuations of the two segments could... More
Moody's Affirms Pfizer's (PFE) Ratings Amid Decision Not to Split Company
September 26, 2016 2:12 PM EDTMoody's Investors Service ("Moody's") affirmed the ratings of Pfizer Inc. (NYSE: PFE) and related subsidiaries, including the A1 senior unsecured long-term rating and the Prime-1 commercial paper rating. At the same time, Moody's revised the rating outlook to stable from negative. This rating action follows the announcement that Pfizer will not pursue a split of its pharmaceutical business.
"Pfizer's decision to keep the business whole removes a key overhang to the credit profile because a split had credit negative implications," stated Michael Levesque, Moody's Senior Vice President.
"The stable rating outlook... More
